Regulation on Advanced Therapy Medicinal Products Eucomed views Dr. Ing. Dario Pirovano May 11, 2006.

Slides:



Advertisements
Similar presentations
Regulation of Advanced Therapies A Biotech SME Perspective May 11, 2006 Gil Beyen CEO - TiGenix N.V. Member of the EuropaBio Advanced Therapies.
Advertisements

Opportunities for input of regions at EU level: Advocating for healthy public policies Caroline Bollars European Week of Regions and Cities 10 October.
From POM to P From POM to P Wellard’s NHS training wellards.co.uk 2004.
The Oviedo Convention from the Perspective of DG Research Dr. Lino PAULA European Commission DG Research, Governance and Ethics Unit.
1. European Commission Status GHS Implementation in the European Community Global Thematic Workshop on Strengthening Capacities to Implement the GHS Johannesburg.
EU Cross-Border Care Directive from the Primary Care perspective Results of a simulation Rita Baeten Gothenburg, 3 September 2012.
The European Data Protection Regulation and research Graham Love Chief Executive Health Research Board 1.
“Reform of the Child Care System: Taking Stock and Accelerating Action” South East Europe 3 – 6 July 2007, Sofia.
I&EHL: EU Pharmaceutical Law André den Exter
Hogan Lovells EU Product Safety and Market Surveillance Reforms How will this impact businesses – Lawyers' view BIICL seminar, 2 October.
S ocial scientists are interested in how different innovative medical technologies including human tissue engineered products (HTEPs) fit into the changing.
Security of Computerized Medical Information: Threats from Authorized Users James G. Anderson, Ph.D. Purdue University.
Privacy and Security Workgroup: Big Data Public Hearing December 8, 2014 Deven McGraw, chair Stan Crosley, co-chair.
Your global support in Europe Over 20 years of experience ELM Pharmaceutica.
The German Health Care System and the Federal Joint Committee (G-BA) Norbert Schmacke FJC/ University of Bremen.
CE2012 – Thursday 20 September The In Vitro Diagnostics View Doris-Ann Williams Chief Executive, BIVDA CC Celebrating 20 years representing the IVD industry.
The Advanced Therapy Medicinal Products Regulation from the European Medicines Agency (EMEA)'s perspective Nathalie Rampal Olmedo EMEA – Directorate –
IPhVWP Polish Presidency, Warsaw October 6 th 2011 Almath Spooner Irish Medicines Board Monitoring the outcome of risk minimisation activities.
) Linked2Safety Project (FP7-ICT – 5.3 ) A NEXT-GENERATION, SECURE LINKED DATA MEDICAL INFORMATION SPACE FOR SEMANTICALLY-INTERCONNECTING ELECTRONIC.
European Parliament Advanced Therapies Hearing May 11, 2006 Advanced Therapies The proposed EU regulation from the viewpoint of a Pharmaceutical company.
Supplies by pharmacists to entities other than patients.
Regional Plan for Regulatory System For Blood, Blood Components and Blood Products Objective/Target: By 2012 all member states will have in place a functioning.
Revision of the Medical Device Directives The case of ‘Borderline’ Products used in a self-care context 48th AESGP Annual Meeting Nice, 6-8 June 2012 Laurent.
E-Health: Proposal and call for a new working group Oslo, 18 April, 2015 E-Health: Preparing for the Helsinki conference Proposal and call for a new working.
Debby Shapero Propp CESO 2004 April 30, 2004 TREATMENT OF MEDICAL DEVICE LICENSING ISSUES IN PROCUREMENT DOCUMENTATION.
INTRODUCTION TO RA.
The competition between innovative and generic pharmaceutical companies intensified in the last decades. The models created by innovative pharmaceutical.
” Particulates „ Characterisation of Exhaust Particulate Emissions from Road Vehicles Key Action KA2:Sustainable Mobility and Intermodality Task 2.2:Infrastructures.
EPHA Presentation EPHA, the EU and Health. EPHA Presentation European Public Health Alliance A network of more that 100 non governmental and not-for-profit.
1 CULTURAL SERVICES IN INTERNATIONAL TRADE: IMPLICATIONS FOR DEVELOPING COUNTRIES Trade Negotiations and Commercial Diplomacy UNCTAD.
EPHA Presentation European Public Health Alliance n A network of 85 non governmental and not- for-profit organisations across Europe working on health.
MEDICAL INNOVATION March What Are The Public Health Benefits of Medical Innovation? Breakthrough medicines New devices Innovative medical procedures.
On Health Care Reforms in Western Europe. An Analytical Approach. Prof. Dr. W.J. de Gooijer.
Documents as quality manual, Annual quality report and product descriptions, Compensation for harm to health Prof. Juozas Galdikas State health care accreditation.
1 EPHA Policy Seminar: The internal market and healthcare services – a step too far? 24 June 2005 Flora Giorgio-Gerlach.
Review of veterinary medicines legislation in 2010 Mario Nagtzaam Unit F2 „Pharmaceuticals“ Directorate-General Enterprise and Industry European Commission.
Legal developments in the Polish Power Sector Arkadiusz Krasnodębski.
IPASA presentation to Portfolio Committee on Health 31 October 2014 Abeda Williams.
© 2004 Moses & Singer LLP HIPAA and Patient Privacy Issues Raised by the New Medicare Prescription Drug Program National Medicare Prescription Drug Congress.
Directorate General for Enterprise and Industry European Commission The New Legislative Framework - Market Surveillance UNECE “MARS” Group meeting Bratislava,
The EU Directive on "Services in the internal market", COM(2004) 2 final/3 Agnese Knabe Project coordinator European Public Health Alliance Civic Alliance.
The Changing Face of EU Legislation Is the EU moving towards the FDA model of pharmaceutical legislation? By Robert Smith Director.
School of Mechanical, Materials and Manufacturing Engineering About this course Biomedical industries provide a rich diversity.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser Ministry of Health, ROMANIA.
Mark Cilia Director Inspectorate & Enforcement 7 th May, 2014 Medicines Authority 203,Level 3, Rue D’Argens, Gzira,GZR 1368 Tel: (+356) Fax:
Date Insert on Master Slide Slide 1 Regulatory Framework within which patients can have safe and more convenient access to medicines Royal College of Physicians.
THE OFFICE FOR REGISTRATION OF MEDICINAL PRODUCTS, MEDICAL DEVICES AND BIOCIDAL PRODUCTS Responsibility in the handling of medical devices.
Prof R T KennedyEMC & COMPLIANCE ENGINEERING 1 EET 422 EMC & COMPLIANCE ENGINEERING.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 1 – Free movement of goods Bilateral.
Introduction to REACH Flavie Guérin U.S. Mission to the EU 15 November 2011.
I farmaci innovativi in una prospettiva europea Giuseppe M.C. Rosano, MD, PhD Cardiovascular and Cell Sciences Research Institute, St George's University.
Update on EU regulatory developments
New legislation impacting IMP
The Citizen in the centre in EU, Bratislava November,2005
Unit for Medical Systems and Devices at Ministry of Health
Overview of public participation in strategic decision-making in the UNECE area David Aspinwall.
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
Supply Of Medical Goods) Bill
Btec First Award in Engineering Module 1 Knowledge Organiser
The Mutual Recognition Regulation
PATIENT NOTICE Data Protection Legislation is Changing From the 25th May, the current UK Data Protection Act 1998 is being replaced by the EU General Data.
AGREEMENT FOR TRANSPARENCY The Case of Mexico
Raising the Standards in European Homeopathy
Effective medicines regulation protect and improve the health of millions of people every day Dr Olexandr Polishchuk World Health Organization Regional.
2.7 Annex 3 – Quality reports
Ethics of the Use of Animals in Scientific Research: Legislation
Presented By: T.M Ramashidzha Metrology Scientist
EU Initiatives to deregulate professions
Presentation transcript:

Regulation on Advanced Therapy Medicinal Products Eucomed views Dr. Ing. Dario Pirovano May 11, 2006

Eucomed – Voice of the Medical Technology Industry in Europe Eucomed represents directly and indirectly 4500 designers, manufacturers and suppliers of: » medical technology » pioneers in human tissue engineering technology including SMEs

Introduction Advanced Therapy Products Many advanced therapy products use multidisciplinary technologies Also many are combined products, i.e. incorporating a medical device and a cellular or tissue part ATP with different modes of action

Examples of human tissue engineered products

Combined product

Non viable tissue engineered product

Viable tissue acting as a medical device

Coverage by the proposed Regulation Non viable: No Viable acting as medicines: Yes Viable acting as Medical Device: diverging views Combined products: –Yes if Medical Device is ancillary; –No if cellular/tissue part is ancillary First test: Is the ATP a medicinal product?

ATMP prepared & used in hospitals for individual patients Proposed exemption from the requirement for a marketing authorisation –This should be limited to a single medical procedure specified for an identified patient under the supervision of the patient’s doctor

It is important that all products containing or being made of human tissue engineered products are covered by Community legislation

What do we suggest Analyse options to cover these products adequately under EU law:  Ensuring a high level of health protection  Adhering to the same four EU policy objectives and  Taking into account the scientific and technical characteristics of the products. Improve the legal certainty for the classification of ATPs and combined products.

Why Eucomed can help Expertise with hybrid, complex & advanced medical devices Eucomed involved since the outset in the discussions on human tissue engineered products

Contact details Eucomed tel. +32 (2) fax: +32 (2) More information on: Eucomed Vademecum

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.